Pramipexole reduces the prevalence of fatigue in patients with Parkinson's disease

Internal Medicine

Volumn 50, Issue 19, 2011, Pages 2163-2168

  Morita, Akihiko ^a   Okuma, Yasuyuki ^b   Kamei, Satoshi ^a   Yoshii, Fumihito ^c   Yamamoto, Toshimasa ^d   Hashimoto, Shiori ^e   Utsumi, Hiroya ^f   Hatano, Taku ^g   Hattori, Nobutaka ^g   Matsumura, Miyuki ^h   Takahashi, Kazushi ⁱ   Nogawa, Shigeru ^j   Watanabe, Yuka ^k   Miyamoto, Tomoyuki ^k   Miyamoto, Masayuki ^k   Hirata, Koichi ^k  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f Tokyo Medical University School of Medicine   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Tokyo Women s Medical University   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKYO DENTAL COLLEGE   (Japan)

^k DOKKYO MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Fatigue; Parkinson's disease; Pramipexole

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG USE; FATIGUE; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSON FATIGUE SCALE; PATIENT ASSESSMENT; RATING SCALE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 80053463220     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5456     Document Type: Article

References (27)

1. Karlsen K, Larsen JP, Tandberg E, Jorgensen K. Fatigue in patients with Parkinson's disease. Mov Disord 14: 237-241, 1999.
2. Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 43: 2016-2018, 1993.
3. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24: 1641-1649, 2009.
4. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Nonrecognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 8: 193-197, 2002.
5. Herlofson K, Larsen JP. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 107: 1-6, 2003.
6. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 22: 2070-2076, 2007.
7. Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behav Neurol 13: 117-121, 2001.
8. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 12: 63-70, 1965.
9. Fahn S, Elton R. Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's Disease, Vol 2. Fahn S, Marsden CD, Calne DB, Goldstein M, Eds. Macmillan Health Care Information, Florham Park, NJ, 1987: 153-163, 293-304.
10. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord 11: 49-55, 2005.
11. Okuma Y, Kamei S, Morita A, et al. Fatigue in Japanese patients with Parkinson's disease: a study using Parkinson Fatigue Scale. Mov Disord 24: 1977-1983, 2009.
12. Folstein MF, Folstein SE, McHugh PR.;Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975.
13. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J. Age-specific norms for the Mini-Mental State Exam. Neurology 38: 1565-1568, 1988.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184, 1992.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 17: 427-442, 1967.
16. Kanda F, Oishi K, Sekiguchi K, et al. Characteristics of depression in Parkinson's disease: evaluating with Zung's Self-Rating Depression Scale. Parkinsonism Relat Disord 14: 19-23, 2008.
17. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 73: 629-635, 2002.
18. Abe K, Hikita T, Sakoda S. Sleep disturbances in Japanese patients with Parkinson's disease--comparing with patients in the UK. J Neurol Sci 234: 73-78, 2005.
19. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 245: S10-S14, 1998.
20. Bxarone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 573-580, 2010.
21. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with Pramipexole. J Neuropsychiatry Clin Neurosci 17: 214-220, 2005.
22. Holman AJ, Myers RR. A randomized, double-blind, placebocontrolled trial of Pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495-2505, 2005.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46: 1121-1123, 1989.
24. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 (long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127: 1696-1702, 1999.
25. Guttman M, Jaskolka J. The use of Pramipexole in Parkinson's disease: are its actions D (3) mediated? Parkinsonism Relat Disord 7: 231-234, 2001.
26. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49: 724-728, 1997.
27. Hauser RA, Schapira AHV, Rascol O, et al. Randomized, doubleblind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 25: 2542-2549, 2010.